Verve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of “Buy” by Analysts

Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) have earned an average rating of “Buy” from the six ratings firms that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the last year is $25.50.

A number of research analysts have issued reports on VERV shares. Guggenheim restated a “buy” rating on shares of Verve Therapeutics in a report on Tuesday, March 25th. William Blair restated an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Finally, Royal Bank of Canada dropped their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th.

Institutional Investors Weigh In On Verve Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC grew its position in Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock valued at $34,000 after acquiring an additional 3,964 shares in the last quarter. IFP Advisors Inc lifted its holdings in Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after buying an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Verve Therapeutics during the fourth quarter valued at about $50,000. Erste Asset Management GmbH purchased a new stake in shares of Verve Therapeutics during the third quarter worth about $56,000. Finally, Impact Partnership Wealth LLC purchased a new position in Verve Therapeutics in the fourth quarter valued at about $70,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Stock Down 1.1 %

Verve Therapeutics stock opened at $5.22 on Tuesday. The firm’s 50-day simple moving average is $6.94 and its 200 day simple moving average is $6.08. Verve Therapeutics has a 52 week low of $4.31 and a 52 week high of $13.24. The firm has a market capitalization of $463.52 million, a PE ratio of -2.12 and a beta of 1.77.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.14. The firm had revenue of $13.08 million during the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. On average, research analysts expect that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.